Overview

A Research Study of VCT220 in Adult Chinese Participants With Obesity

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-03-27
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess how VCT220 tablets affect the bodyweight in obese or overweight adult participants. Participant will be randomly assigned to the high-dose group, low-dose group, or placebo group. Each participant will take the study drug orally once daily for 12 months.
Phase:
PHASE3
Details
Lead Sponsor:
Vincentage Pharma Co., Ltd